Pancreatic cancer has one of the lowest survival rates for all cancers, but there are some people who achieve long-term survival. We are looking at those patients, with the goal of identifying what are some treatments and experiences that do work. Learning about treatment combinations and unique therapies that have led to success can open doors for where our research should be focused moving forward.
The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.
This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.
Do you have ovarian cancer that has come back after your first round of treatment? if so you may be able to participate in a research study to test if MIRV in combination with bevacizumab as maintenance therapy, can help to prevent your cancer from returning or delaying your cancer's return.
Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.
This study tests whether the investigational device CT-155 improves negative symptoms associated with schizophrenia.
Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.
To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.
Researchers want to learn more a new medication that could be used to treat adults with Eosinophilic Esophagitis (also called "EoE").
Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.